Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

OssDsign

2.98 SEK-6.58 %20.11, 17.29
Less than 1K followers

OSSD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-6.58 %
-7.60 %
-25.03 %
-28.19 %
-73.72 %
-72.25 %
-53.29 %
-65.83 %
-82.85 %

OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.

Read more
Market cap
329.67M SEK
Turnover
1.43M SEK
Revenue
180.16M
EBIT %
-25.95 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
16.2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release04.11.2026, 06.49

DNB Carnegie Access: OssDsign: Still awaiting sales recovery – Q3 review

OssDsign
Third party research03.11.2026, 16.11

OssDsign: Waiting for sales momentum to improve - ABG

* Transition of US sales team to drive a turnaround in sales generation * No change to mid-term targets * Fair value range revised down to SEK 3.1-5.1 (3.2-5.4) Miss on sales, but opex better in Q3 Q3 marked another quarter with soft sales momentum but...

OssDsign
Third party research03.11.2026, 09.02

OssDsign: Soft sales development continues - ABG

* 42% beat (less negative) on adj EBIT but miss on sales * -20% organic growth (ABGSCe -18%) * No change in outlook Q3 results OssDsign reported a mixed set of numbers in Q3 with 3% lower sales, gross margin in line, but good cost control on opex resulting...

OssDsign

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release03.11.2026, 08.26

DNB Carnegie Access: OssDsign: Unlikely to change current sentiment – Q3 initial

OssDsign
Regulatory press release03.11.2026, 07.00

OssDsign AB (publ) publishes Q3 2026 interim report

OssDsign
Third party research27.10.2026, 12.56

OssDsign: No pick up in growth yet - ABG

* We expect soft sales momentum for Q3e * Negative earnings revisions on lower sales * Q3'26 results due 3 November Q3'26 expectations We do not expect to see any major change in OssDsign's sales development in Q3e, compared with previous quarters during...

OssDsign
Press release14.10.2026, 06.54

DNB Carnegie Access: OssDsign: Q3 too early for the turnaround – Q3 preview

OssDsign
Press release31.08.2026, 20.11

DNB Carnegie Access: OssDsign: Highlights from DNB Carnegie Micro Cap Day

OssDsign
Third party research19.08.2026, 06.55

OssDsign: Soft commercial momentum near-term - ABG

* Expected return to growth pushed out to Q4 * Adj. EBIT cut by 2.6%-3.6% for '26e-'28e * Fair value range revised down to SEK 3.8-6.2 (4.0-6.3) Small miss on sales, but lower opex in Q2 OssDsign reported mixed results in Q2: sales were 1% below expectations...

OssDsign
Press release19.08.2026, 06.49

DNB Carnegie Access: OssDsign: Growth recovery remains elusive – Q2 review

OssDsign
Press release18.08.2026, 08.14

DNB Carnegie Access: OssDsign: Q2 initial – Weak quarter as expected

OssDsign
Third party research18.08.2026, 07.57

OssDsign: Beat on EBIT on lower sales - ABG

* 10% beat on adj EBIT but lower saIes * -16% organic growth (ABGSCe -15%) * No change in outlook, Q3 seasonally soft Q2 results OssDsign reported a mixed set of numbers in Q2 with 1% lower sales, lower gross margin, but good cost control on opex resulting...

OssDsign
Regulatory press release18.08.2026, 07.00

OssDsign AB (publ) publishes Q2 2026 interim report

OssDsign
Third party research12.08.2026, 07.00

OssDsign: Waiting for the growth to return - ABG

* Sequentially flattish, but -15% organic drop in sales in Q2e * We assume a recovery in sales growth in H2'26e * Q2'26 results due 18 August Q2'26 expectations We expect sales development to have stabilised in Q2, at a similar level to Q1'26, but lower...

OssDsign
Press release11.08.2026, 18.58

DNB Carnegie Access: OssDsign: We expect a sluggish Q2, eyeing H2 recovery – Q2 preview

OssDsign
Press release25.06.2026, 17.30

OssDsign AB: OssDsign appoints Adam McCollister as new Vice President of Sales

OssDsign
Press release10.06.2026, 10.55

Annual General Meeting held in OssDsign AB

OssDsign
Press release03.06.2026, 10.21

OssDsign AB announces updated proposal regarding board fees ahead of the annual general meeting 2026

OssDsign
Press release06.05.2026, 07.19

DNB Carnegie Access: OssDsign: Needs to prove slowdown is transitional – Q1 review

OssDsign
Third party research05.05.2026, 13.50

OssDsign: Reset underway ahead of H2'26 - ABG

* Q1 in line with pre-announced numbers * Minor estimate revisions, H2'26 the key catalyst * Fair value range unchanged at SEK 4.0-6.2 Weak GM in Q1, opex offset Q1 sales confirmed the pre-announced number of SEK 36.9m (0% vs. ABGSCe) with an organic...

OssDsign